Tag: helix biopharma

May 1, 2019

Helix BioPharma Gives Update on L-DOS47 Phase II Study

Helix BioPharma announced the Trial Steering Committee reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.
June 8, 2018

Helix BioPharma Closes Private Placement

Helix BioPharma (TSX:HBP) an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it...
February 23, 2018

Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities

Helix BioPharma (TSX:HBP) a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today...
December 14, 2017

Helix BioPharma Shares Fiscal 2018 Q1 Financial Results

Helix BioPharma announced its financial results for the first quarter of their 2018 fiscal year.
September 28, 2017

Helix BioPharma Gets FDA Approval to Accelerate Dose Escalation in Trial

Helix BioPharma announced that the FDA approved an amendment to their phase I study, protocol LDOS001, to accelerate the dose...
September 1, 2017

Helix BioPharma Closes Private Placement

Helix BioPharma announced it closed a private placement financing option, which resulted in gross proceeds of $1,311,000.
August 22, 2017

Helix Announces Peer-Review Publication of V-DOS47 in Frontiers in Immunology Journal

Helix BioPharma shared the publication of a peer-reviewed V-DOS47 manuscript in "Frontiers in Immunology" journal.